TIDMABC
RNS Number : 9236B
ABCAM Plc
04 November 2009
?
+---------------------------------------+---------------------------------------+
| For immediate release | 4 November 2009 |
+---------------------------------------+---------------------------------------+
("Abcam" or "the Company")
Director and PDMR Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that
markets antibodies via its own online catalogue, announces the following
transactions undertaken by employees of the Company:
On 3 November 2009, Jim Warwick, as Executive Director of the Company, exercised
share options over 4,218 ordinary shares of 1 pence each in the Company at an
exercise price of 224p per share. Following this transaction, Mr Warwick's total
beneficial interest in the Company is 857,738 ordinary shares representing
approximately 2.4 per cent. of the current issued share capital of the Company.
Also on 3 November 2009, Jane Cooke, a PDMR of the Company, exercised share
options over 3,375 ordinary shares of 1 pence each in the Company at an exercise
price of 224p per share. Following this transaction, Mrs Cooke's total
beneficial interest in the Company is 3,724 ordinary shares representing
approximately 0.01 per cent. of the current issued share capital of the Company.
For further information please contact:
+-----------------------------------------+------------------------------------+
| Abcam | + 44 (0) 1223 696000 |
+-----------------------------------------+------------------------------------+
| Jonathan Milner, Chief Executive | |
| Officer | |
+-----------------------------------------+------------------------------------+
| Jeffrey Iliffe, Chief Financial Officer | |
+-----------------------------------------+------------------------------------+
| | |
+-----------------------------------------+------------------------------------+
| Numis Securities | + 44 (0) 20 7260 1000 |
+-----------------------------------------+------------------------------------+
| Michael Meade / Nick Westlake - | |
| Nominated Adviser | |
+-----------------------------------------+------------------------------------+
| James Black - Corporate Broking | |
+-----------------------------------------+------------------------------------+
| | |
+-----------------------------------------+------------------------------------+
| Buchanan Communications | + 44 (0) 20 7466 5000 |
+-----------------------------------------+------------------------------------+
| Mark Court / Mary-Jane Johnson / Stasa | |
| Filiplic | |
+-----------------------------------------+------------------------------------+
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA,
Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and
trades under the ticker symbol ABC. The Company produces and distributes its own
and third-party produced antibodies to academic and commercial users throughout
the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed
technical product data sheets. All the antibodies are sold under the Abcam brand
name and the Company's vision is to build the world's largest online resource of
high-quality and commercially viable antibodies. Abcam now has an online
catalogue of over 56,000 products, most of which are antibodies, from over 250
suppliers and employs 243 staff in its four operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSKZLBBKFBEFBE
|